Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine

Vaccine

Volumn 20, Issue 3-4, 2001, Pages 352-358

  De Kleijn, Ester ^a   Van Eijndhoven, Lilian ^b   Vermont, Clementien ^a   Kuipers, Betsy ^b   Van Dijken, Harry ^b   Rümke, Hans ^b   De Groot, Ronald ^a   Van Alphen, Loek ^b   Van den Dobbelsteen, Germie ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Children; Isotype distribution; Meningococcal B vaccine

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4; OMV VACCINE; PORIN A; PROTEIN; UNCLASSIFIED DRUG; VACCINE;

AGE; BLOOD ANALYSIS; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; NETHERLANDS; NONHUMAN; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ACTIVITY; VACCINATION;

ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN ISOTYPES; MENINGOCOCCAL VACCINES; PORINS; VACCINATION;

EID: 0035851320     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00371-1     Document Type: Conference Paper

References (29)

1. Aspects of the molecular structure of IgG subclasses
2. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination
3. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine
4. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration
5. Comparison among opsonic activity, anti-meningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccines after immunization with a serogroup B outer membrane vesicle vaccine
6. IgG subclass changes in response to vaccination
7. IgG subclasses in bacterial infections
8. Measurements of serum IgA and IgG activities to dietary antigens. A prospective study of the diagnostic usefulness in adult coeliac disease
9. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination
10. Specific IgG4 responses during chronic and transient antigen exposure in aspergillosis
11. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
12. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil
13. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy
14. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine
15. Neisseria meningitidis subtype nomenclature
16. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
17. Immunogenicity and safety of a hexavalent meningococcal outer membrane vesicle vaccine in children 2-3 and 7-8 years of age
18. Humoral immune responses to Neisseria meningitidis in children
19. Production, characterisation and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine
20. Isolation of Neisseria meningitidis mutants deficient in class 1 (PorA) and class 3 (PorB) outer membrane proteins
21. Specificity of human bactericidal antibodies induced with a hexavalent meningococcal outer membrane vesicle vaccine
22. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
23. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile
24. Immunogenicity of two serogroup B outer membrane protein meningococcal vaccines: A randomised controlled trial in Chile
25. Surface structures and secreted products of meningococci
26. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine
27. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides
28. Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory
29. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine